Heme/Onc Fellow @DanaFarber/@MassGeneralBrigham. Former @BrighamMedRes and @Georgetown MD/PhD. Passionate about true crime podcasts, reality TV, and Taco Bell.
Joined December 2011
- Tweets 4,502
- Following 1,876
- Followers 15,899
- Likes 31,172
572 Photos and videos
Pinned Tweet
29 Oct 2025
Iβm so excited to share my third and final first-author publication from my PhD!! We discovered NK cells express fibroblast activation protein (FAP) and use it to migrate into tumors! FAP overexpressing NK cells reduced pancreatic cancer growth in mice! tinyurl.com/FAPNK1
18
54
445
72,160
Got to celebrate the end of the year with some of the best residents/fellows/friends around.
@BrighamMedRes
2
57
5,395
Today I learned you should not give methylnaltrexone to patients with constipation who have not had a BM for 5 days because it can cause perforation if there is a distal blockage. If no BM for more than 5 days enemas are the standard.
5
54
4,646
Today I learned that while CML is unlikely to cause leukostasis despite causing high white counts, it can rarely cause priapism due to leukostasis. Priapism is more common in patients with CML than other leukemias.
4
5
78
7,923
An iconic use of the emergency notification systemπ¦βοΈπ₯³
4
1
43
2,103
It was actually de novo metastatic ER HER2- breast cancer! Repeat testing confirmed extremely high TMB. Interesting!
A TMB of 285 has to be some sort of record
2
2
21
6,138
This is amazing! And this hopefully represents a cascade of new and improved treatments coming for patients with pancreatic cancer with the advent of these new targeted therapies
Last year, we reported that KRAS PRMT5 is synergistic in MTAP-null PDAC (doi.org/10.1158/0008-5472.CAβ¦). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.
RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD
1
1
15
2,937
Allison Fitzgerald, MD, PhD retweeted
Jun 9
It's going to be a different kind of meeting this year, I imagine...
Submit an abstract by July 13 for the AACR Conference on Pancreatic Cancer (Sept 25-28; San Diego), chaired by Andrew J. Aguirre, Florencia McAllister, Kenneth P. Olive, Eileen OβReilly, Diane M. Simeone, and Colin D. Weekes.
brnw.ch/21x3bqM
#AACRpan26 @MadameSurgeon
5
16
2,818
A good tidbit is the only time peripheral blasts can be benign is during count recovery (even in pts w/ leukemia). The only definitive way to differentiate benign vs malignant is bone marrow bx, but the presence of other cells on the diff (myelocytes, metas) suggests benign.
1
3
30
3,484
Today I learned that:
By age 60, 10% of US adults are cancer survivors.
By age 80, ~30% men and ~20% women are cancer survivors.
6
10
72
5,547
Iβve thought this for a long time. While itβs amazing to see the advances in technology, these advances are outpacing our ability to make clinically meaningful discoveries. We need to get better at using the data we can generate.
1/ Another single-cell study drops.
500,000 cells sequenced.
More UMAP plots. More clusters.
But hereβs the question:
Are we learning moreβor just counting better? π§΅
3
4
31
6,251
And in celebration of having a month left of my first year of fellowship- My first set of new plants since starting residency! Iβm trying railing planters for the first time (we donβt have a yard so this is the closest we can get to a garden)! Letβs see how it goes!
Iβm hopeful I can get back to some hobbies once my clinical year of fellowship ends this July. In med school I loved my plants but once residency started they all nearly died π
4
66
7,486
Today I learned that ALL is a uniquely hyper-methylated malignancy. This causes hypermethylation of asparagine synthetase, decreasing expression. ALL cells then canβt make asparagine. Asparaginase depletes exogenous asparagine, resulting in ALL cell death.
4
19
114
7,152
Today is national donut day. Please plan accordingly!
4
1
24
2,130
Today I learned that although weβre taught to avoid G-CSF in AML, some AML regimens use it. Cytarabine (chemo) is s-phase specific bc itβs a nucleoside analog that inhibits DNA synthesis. G-CSF primes leukemic cells by pushing them into S-phase, enhancing chemo efficacy.
7
11
122
13,188
Allison Fitzgerald, MD, PhD retweeted
The timing could not be worse. At #ASCO2026, we saw #daraxonrasib double survival in #PDAC, a reminder that decades of NIH research investment are paying off. Yet federal research funding is being cut. The biggest victims won't be scientists... They'll be future patients
9
45
196
25,206
Allison Fitzgerald, MD, PhD retweeted
ABBV-706 [#SEZ6 #ADC ] in 2L SCLC showed ORR 82% (14/17), with activity even in platinum-refractory/resistant disease and CBR >94% @SclcSMASHERS
Early days, but an agent to continue to watch in relapsed SCLC @ASCO #ASCO26 #LCSM @LaurenByersMD @alissajcooper @drshieldsmd
2
7
24
1,847
Me to my toddler: sneeze into your elbow!
My toddler: sneezes into her hands *looks me dead in the eyes* wipes it on my face
7
70
4,865
Very cool!! Excited to see this in practice!
ππ¨π‘π§-ππ’π₯π₯π’ππ¦ ππ’ππ‘π¨π¦, ππ, ππ‘π
@John_Will_I_Am
After almost 2 years of work, I'm beyond thrilled to share TESSERA π
𧬠A foundation model for the cancer genome.
One genomic fingerprint β
π©Ί Diagnosis
π Prognosis
π§ͺ Prediction
π Preprint LIVE β biorxiv.org/content/10.64898β¦
#CancerGenomics #FoundationModels #AIinMedicine
1
2
27
8,589
Today I learned that for differentiating hypereosinophilia etiologies, the degree of eosinophilia is rarely helpful unless eosinophils >20k. Counts this high are rarely caused by infections, more likely a clonal process. Parasites rarely cause eos greater than 5k
Differential:
6
13
107
5,885
If your main criticism of a new cancer drug that doubles overall survival is βitβs not a cureβ, please work on developing intellectually rigorous clinical trial assessments.
And while weβre at it, how about some empathy? An extra YEAR of life is nothing to balk at
16
15
276
18,666